In addition, lysine demethylase 5 A (KDM5A) increases resistance to multiple anticancer drugs, including breast cancer resistance to erlotinib and lung cancer cell resistance to gefitinib, by removing histone methylation [16, 17]. Here, KDM5A is linked to lung carcinoma.